<DOC>
	<DOCNO>NCT00039390</DOCNO>
	<brief_summary>This phase I trial study side effect best dose gefitinib capecitabine treat patient advance solid tumor . Biological therapy gefitinib may interfere growth tumor cell slow growth solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining gefitinib capecitabine may kill tumor cell</brief_summary>
	<brief_title>Gefitinib Capecitabine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose gefitinib capecitabine patient advance solid tumor . II . Determine dose-limiting toxic effect regimen patient . III . Determine pharmacologic profile regimen patient . OUTLINE : This dose-escalation study gefitinib capecitabine . Patients receive oral gefitinib daily day 1-14 oral capecitabine twice daily day 8-21 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gefitinib capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 11-41 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm advanced solid tumor refractory standard therapy standard therapy exist No uncontrolled brain metastasis , include symptomatic lesion lesion require treatment ( e.g. , glucocorticoid and/or anticonvulsant ) Performance status ECOG 02 At least 12 week WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal ( 5 time ULN liver metastasis present ) Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No active infection No serious concurrent systemic disorder would preclude study participation No malignancy No prior hypersensitivity sulfonamidebased drug , nonsteroidal antiinflammatory drug , fluorouracil No document dihydropyrimidine dehydrogenase deficiency Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent immunotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent hormonal therapy At least 28 day since prior radiotherapy No concurrent radiotherapy At least 4 week since prior investigational agent No concurrent experimental medication No concurrent drug know induce cytochrome P450 3A4 ( e.g. , rifampin , phenytoin , carbamazepine , barbiturate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>